NextCure, Inc. (NXTC)
Nasdaq · Healthcare · Biotechnology
$5.05−0.79%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $23.1M
- 52-week range
- $1.55 – $15.74
- 52-week change
- −17.58%
- EPS (trailing)
- −$8.71
Fiscal year to Dec 2025
- Net income
- −$55.8M
- Diluted EPS
- −$19.65
From the company’s annual report on SEC EDGAR.
About NextCure, Inc.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Baltimore, Maryland.
Headquarters: Baltimore, United States · 40 employees · nextcure.com